Seed funding is not enough to carry Nigerian digital health startups to scale
Nigeria’s digital health sector has attracted growing attention because it promises to close persistent gaps in access, coordination, and delivery across a strained health system. Yet a narrative review published in Health economics review argues that early capital alone has not been enough to move many startups from promising pilots to durable, scaled businesses. The central problem is not a lack of ideas or even a lack of money at the outset. It is the difficulty of turning a seed round into a functioning enterprise inside an environment where regulation, infrastructure, workforce constraints, and patient trust all pull in different directions.
The review synthesized investment reports, case studies of major Nigerian health-tech companies, and comparative lessons from other markets. Its framing is straightforward: seed-stage enthusiasm has risen, venture activity peaked in 2021, and yet the number of startups that translate those early wins into sustained growth remains small. In practical terms, a startup may secure backing, build a product, and even attract attention, only to stall when the harder work begins—distribution, reimbursement, interoperability, hiring, and compliance. For digital health, the product is only one piece of the care pathway.
One sentence captures the sector’s central failure point: capital opens the door, but it does not remove the walls.
Regulatory friction and weak infrastructure slow the path from prototype to routine care
The review places regulatory hurdles near the center of the post-seed problem. Health technology does not operate in a vacuum; it has to function inside licensing frameworks, data governance rules, clinical validation expectations, and procurement systems that were not designed for fast-moving software companies. A startup that can demonstrate technical promise may still face delays if approvals are slow, standards are unclear, or public-sector processes are difficult to navigate. Those barriers become even more consequential when investors expect rapid scale, because health systems move at a different pace than consumer apps.
Infrastructure problems compound the issue. Digital health platforms depend on reliable internet access, power supply, device availability, and basic system interoperability. Where those inputs are unstable, the cost of expansion rises quickly. Services that appear scalable on paper become far more expensive to deliver consistently across regions, especially outside major urban centers. The result is a widening gap between venture-stage optimism and operating reality. A company can build for growth and still find that the surrounding system cannot support routine uptake.
Trust is another structural barrier. Patients, clinicians, and institutions are not guaranteed to adopt a new digital platform simply because it exists. Health care relies heavily on credibility, and in settings where users are unfamiliar with a platform or wary of data use, adoption can lag even when the service is useful. In digital health, trust functions like an invisible infrastructure. When it is weak, every other part of the model becomes harder to execute.
Case examples show how fragile scale can be after early success
The review uses case narratives to illustrate how uneven the post-seed path can be. Helium Health is presented as an example of regional expansion, demonstrating that growth is possible when business strategy, market fit, and operational execution align. The company’s trajectory suggests that a Nigerian health-tech startup can extend beyond a single market when it solves real workflow problems and secures the partnerships needed for expansion.
54gene offers a different lesson. The company’s post-pandemic collapse is used to show how quickly momentum can unwind when a business model meets market headwinds and system-level constraints. Digital health investors often prize scale, but scale in health care is fragile when the underlying economics, regulation, and demand environment shift. A company may appear well positioned during a period of abundant capital and public interest, then struggle once external conditions change. The collapse is a reminder that seed funding can create visibility without guaranteeing durability.
These examples matter because they reflect two distinct pathways. One shows gradual expansion supported by operational discipline and market alignment. The other shows how quickly a high-profile company can lose traction when structural support is missing. In both cases, the deciding factor is not simply how much money entered the company at the start, but whether the ecosystem could absorb and sustain what the company built.
Follow-on capital, public-private partnerships, and talent pipelines may matter more than seed rounds alone
The review argues that support after the seed stage is where the system becomes decisive. Specialized follow-on funds could help bridge the period when startups have moved beyond prototype status but have not yet become attractive to mainstream growth investors. That stage is often the most vulnerable, because companies need patient capital to refine operations, navigate regulation, and prove they can deliver at scale without burning through resources.
Public-private partnerships may also play a larger role than they do now. In a sector tied so closely to public health delivery, cooperation with government agencies, hospitals, payers, and regulators can reduce uncertainty and create clearer routes to adoption. These partnerships can help align innovation with actual system needs instead of forcing startups to guess which products the market can absorb. They may also create more credible pathways for procurement and integration, both of which are essential in health care.
The talent gap is harder to fix, but no less important. Digital health startups need technical teams, product managers, compliance expertise, clinical advisers, and operators who understand both software and health-system realities. If those skills are scarce, growth becomes lopsided. Engineering talent without health-sector fluency can produce elegant tools that do not fit clinical workflow. Health-sector expertise without digital execution can slow product development. The review treats this as a binding constraint, not a secondary concern.
Lessons from Kenya and India point to ecosystem design, not isolated startups
Comparative insights from Kenya and India reinforce the review’s broader argument: successful health-tech scale depends on ecosystem design. Those markets have benefited from stronger support structures, more established pathways for innovation, and clearer mechanisms that help startups move beyond the earliest financing round. The lesson is not that Nigeria must copy another country’s model in full. It is that isolated startup success is hard to sustain when the surrounding system offers little help after the first infusion of capital.
The policy implication is direct. If Nigeria wants its digital health startups to deliver lasting impact, financing cannot stop at seed stage. Regulatory clarity, infrastructure investment, trust-building, specialized capital, and stronger links between innovators and the health system all have to move together. Without those supports, venture peaks may continue to produce short bursts of activity without durable scale.
For Nigerian digital health, the post-seed gap is the real bottleneck. The review’s message is blunt: startup growth will remain constrained until the ecosystem is built to carry companies past their first round and into long-term operation.